Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 5, 2018

Primary Completion Date

August 27, 2021

Study Completion Date

December 31, 2025

Conditions

GliomaGlioblastoma

Interventions

DRUG

ruxolitinib

Starting dose ruxolitinib 10 mg twice daily

RADIATION

radiation

60gy for 6 weeks

DRUG

temozolomide

75mg/m2

Trial Locations (1)

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors

lead

Case Comprehensive Cancer Center

OTHER